SUPN Straddle Strategy

SUPN (Supernus, Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.

Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates. Its products are sold primarily in the United States, with additional markets including Canada, Australia, France, and Germany. The company was formed through the November 2026 merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and is headquartered in Rockville, Maryland.

SUPN (Supernus, Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $1.73B, a trailing P/E of 7.79, a beta of 0.52 versus the broader market, a 52-week range of 25.92-43.2, average daily share volume of 2.5M, a public-listing history dating back to 2012, approximately 827 full-time employees. These structural characteristics shape how SUPN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.52 indicates SUPN has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 7.79 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price. SUPN pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.

What is a straddle on SUPN?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

SUPN snapshot

As of November 13, 2026, spot at $29.69, ATM IV 64.60%, IV rank 31.97%, expected move 18.52%. The straddle on SUPN below is built from the November 13, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this straddle structure on SUPN specifically: SUPN IV at 64.60% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 18.52% (roughly $5.50 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SUPN expiries trade a higher absolute premium for lower per-day decay. Position sizing on SUPN should anchor to the underlying notional of $29.69 per share and to the trader's directional view on SUPN stock.

SUPN straddle setup

The SUPN straddle below is built from the November 13, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SUPN at $29.69 on that close, the first option leg uses a $29.87 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SUPN chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SUPN shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$29.87$2.48
Buy 1Put$29.87$2.95

SUPN straddle risk and reward

Net Premium / Debit
-$542.50
Max Profit (per contract)
Unbounded
Max Loss (per contract)
-$539.92
Breakeven(s)
$24.45, $35.30
Risk / Reward Ratio
Unbounded

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

SUPN straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on SUPN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

SUPN straddle profit and loss curve at expiration with breakevens and current spot markedSUPN straddle payoff at expiration-$500$0$500$1000$1500$2000$10$20$30$40$50Underlying Price ($)P&L at Expiration ($)BE $24.45BE $35.30Spot $29.69
P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.
Underlying Price% From SpotP&L at Expiration
$0.01-100.0%+$2,443.50
$6.57-77.9%+$1,787.15
$13.14-55.8%+$1,130.80
$19.70-33.6%+$474.44
$26.26-11.5%-$181.91
$32.83+10.6%-$246.74
$39.39+32.7%+$409.61
$45.95+54.8%+$1,065.96
$52.52+76.9%+$1,722.31
$59.08+99.0%+$2,378.67

When traders use straddle on SUPN

Straddles on SUPN are pure-volatility plays that profit from large moves in either direction; traders typically buy SUPN straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

SUPN thesis for this straddle

The market-implied 1-standard-deviation range for SUPN extends from approximately $24.19 on the downside to $35.19 on the upside. A SUPN long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current SUPN IV rank near 31.97% is mid-range against its 1-year distribution, so the IV signal is neutral; the straddle thesis on SUPN should anchor more to the directional view and the expected-move geometry. As a Healthcare name, SUPN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SUPN-specific events.

SUPN straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SUPN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SUPN alongside the broader basket even when SUPN-specific fundamentals are unchanged. Always rebuild the position from current SUPN chain quotes before placing a trade.

Frequently asked questions

What is a straddle on SUPN?
A straddle on SUPN is the straddle strategy applied to SUPN (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With SUPN stock at $29.69 on the November 13, 2026 close, the strikes shown on this page are snapped to the nearest listed SUPN chain strike and the premiums come straight from that session's bid/ask midpoint.
How are SUPN straddle max profit and max loss calculated?
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the SUPN straddle priced from the November 13, 2026 end-of-day chain at a 30-day expiry (ATM IV 64.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$539.92 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a SUPN straddle?
The breakeven for the SUPN straddle priced on this page is roughly $24.45 and $35.30 at expiration, derived from the November 13, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The SUPN market-implied 1-standard-deviation expected move in the same options snapshot is approximately 18.52%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on SUPN?
Straddles on SUPN are pure-volatility plays that profit from large moves in either direction; traders typically buy SUPN straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current SUPN implied volatility affect this straddle?
SUPN ATM IV is at 64.60% with IV rank near 31.97%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related SUPN analysis